New pill could spare kids with rare bone disease from chemo
NCT ID NCT07371182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new daily oral drug called luvometinib in children aged 0-18 with Langerhans cell histiocytosis (LCH) that affects certain bones. LCH is a rare condition where immune cells build up and can cause bone damage. The drug targets a faulty cell signal found in nearly all cases. Researchers want to see if this pill can keep the disease from coming back and improve quality of life, with fewer side effects than standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
-
Anhui Provincial Children's Hospital
RECRUITINGHefei, China
-
Jiangxi Provincial Children's Hospital
RECRUITINGNanchang, Jiangxi, China
-
Kunming Children's Hospital
RECRUITINGKunming, Yunan, China
-
The First Affiliated Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, Xinjiang, China
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
-
The Second Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
-
West China Second Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Xi'an Children's Hospital
RECRUITINGXi'an, Shaanxi, China
-
Xi'an Northwest Women's and Children's Hospital
RECRUITINGXi'an, Shaanxi, China
-
Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital
RECRUITINGZunyi, Guizhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- New targeted drug combo aims to curb relapse in kids with rare immune disorder
- Scientists hunt for genetic clues in rare blood disorders
- Old drug, new hope: lenalidomide tackles rare histiocyte cancers
- New pill shows promise for rare childhood diseases
- New hope for rare cancer: drug cocktail targets stubborn LCH